/

NewLimit

Developing epigenetic reprogramming medicines to extend human healthspan.

Biotechnology newlimit.com ↗

Company facts

Founded: 2021
Employees: 50
Headquarters: United States
Type: Private
Funding: Series B · $45M · 2025